F. Hoffmann-La Roche Ltd: FDA accepts application for Roche's Gazyva/Gazyvaro for the treatment of the most common form of lupus

AI Briefing

• – FDA accepts Roche's Gazyva/Gazyvaro application for lupus treatment
• – Phase III data shows significant reduction in disease activity
• – Gazyva/Gazyvaro in SLE treatment under FDA review